While leading CDMOs push backlogs into the tens of billions, second-tier players hold large peptide order books too - Jiuzhou >RMB 5bn in TIDES, Apelo >RMB 7.8bn in commercial orders, Asymchem +54% backlog. But an order is neither revenue nor profit. Using three Q3 earnings reports, this piece dissects the order-to-revenue-to-profit conversion rate across project stage, utilization and margin mix, answering an under-asked question: how fast, and at what margin, will these orders actually land?

Q3 earnings season made peptide orders the brightest line in every report: Jiuzhou Pharmaceutical's TIDES backlog above RMB 5bn, Apelo Pharmaceutical's commercial orders to be delivered above RMB 7.8bn, Asymchem's backlog up 54% - each number bigger than the last. Yet the income statement tells a different story: Jiuzhou's first-nine-month revenue still fell 5.38% and net profit 17.5%; Apelo's recurring net profit dropped 12.22%; only Asymchem posted an 81.5% jump in Q3 net profit. That gap between order value and performance is the question second-tier CDMOs most need to answer in 2026: how fast, and at what margin, will these peptide orders be converted?

1. Backlog is the most misread number in the report

Backlog is a candidate pool of future revenue, not revenue already earned. It does not distinguish early-clinical from commercial projects, does not commit to delivery timing, and does not lock in margin. Take Jiuzhou: the company discloses 'over RMB 5bn in orders over the next 12 months,' with commercial and late-clinical projects a high share. But the same report shows CDMO utilization of only about 70% - Ruibo Suzhou's small-molecule workshop above 80%, Zhejiang Ruibo ramping as Phase III projects enter validation batches. In other words, a meaningful share of orders is still signed-but-unconverted. The company is candid: growth remains 'constrained by production scale,' and its peptide commercial line is still under construction.

Apelo offers another sample. It disclosed over RMB 7.8bn in commercial orders to be delivered over three years, with CDMO project numbers up 38% to 1,715 - funnel intake expanding far faster than revenue, a classic 'reserve first, conversion later' pattern. Its Q3 CDMO gross margin of 35.52% was below the 40.39% nine-month figure, not because of price cuts but because of delivery mix: clinical projects accounted for more than commercial ones in Q3. Clinical batches are small and process-scale-up amortization is incomplete, so margins are naturally lower. For orders to become high-margin revenue, projects must first reach commercial scale-up.

Table 1 Three second-tier CDMOs in Q3: order value vs conversion capacity (cxdmo.com)
CompanyPeptide/new-modality order signalRevenue & profitConversion constraint
Jiuzhou PharmaTIDES backlog >RMB 5bn; 20+ new projects in 9M (GLP-1/Parkinson's/autoimmune)9M revenue RMB 3.94bn (-5.38%); net profit RMB 617m (-17.5%); Q3 back to growthCDMO utilization ~70%; peptide commercial line building; capex only ~RMB 1bn/yr
Apelo PharmaCommercial orders >RMB 7.8bn (3 yr); CDMO projects 1,715 (+38%)9M CDMO revenue RMB 2.05bn (+21.4%); Q3 RMB 642m (+41%); recurring profit -12.22%Q3 margin 35.52% (clinical-heavy mix); ~RMB 2bn expansion just started
AsymchemBacklog +54%; Q3 new orders ~+30%; emerging business +50.2%9M revenue RMB 5.40bn (+16.5%); Q3 net profit +81.5%Q4 must book 28%-30% of full-year revenue; emerging-business margin only 30.95%
Figures from Q3 2026 reports and public institutional calls. Order definitions (12-month / 3-year / cumulative) differ, so absolute values are not directly comparable.

2. Three gates between orders and revenue: stage, capacity, certification

At least three gates sit between an order and revenue. First is project stage: a new-modality project typically needs 18 to 36 months from signing to PPQ (process performance qualification) and then to commercial-batch revenue. Jiuzhou's 25%+ new small-molecule CDMO projects did not show up in revenue immediately precisely because they are still early. Second is capacity: Jiuzhou's roughly RMB 1bn annual capex is about one-tenth of WuXi AppTec's RMB 7.5-8.5bn, meaning it cannot spread across the board and must 'pick points' among peptide commercialization, conjugation and oligonucleotides. Third is certification: Asymchem repeatedly stresses in calls that winning large-client orders requires a 'ticket' beyond hardware - quality agreements, PAI dynamic inspections, commercial batch release records, change-control history - none of which can be shortened by capex or bought with a lower price.

These three gates together explain why 'capacity without certification' and 'certification without capacity' coexist - and why the two should not carry the same valuation multiple. Asymchem passing a PAI dynamic inspection in Q3 upgraded an antibody line from 'can take clinical batches' to 'can take commercial scale-up' - a revenue event, not a quality event. Jiuzhou appointing a Novartis-system executive as president is, in essence, pairing its RMB 5bn of orders with the 'software' team able to manage GMP deviation and global audits.

3. Three indicators worth more than order value

If backlog misleads, what are the reliable leading indicators? First, the schedule for new projects entering PPQ - it determines when orders start becoming revenue. Second, utilization at core sites - the 10 percentage points between Jiuzhou's 70% overall and Ruibo Suzhou's 80%+ is the truest picture of a second-tier CDMO: not a lack of orders, but orders concentrated in a few sites and a few stages. Third, delivery mix and the margin curve - Apelo's Q3 margin dip came from a clinical-heavy mix; if Q4 commercial share rises as expected, 35.52% was a quarterly blip, and if not, a structural downshift.

Translated to valuation, a clear shift is under way: the pricing anchor for second-tier CDMOs is moving from 'backlog value' to 'order-to-revenue conversion rate.' The numerator is two continuously checkable indicators - the PPQ entry schedule and core-site utilization; the denominator is that ever-growing order figure. Jiuzhou's management change, Asymchem's PAI pass, and Apelo's Q4 delivery outlook are each statements on this conversion curve.

Backlog is a candidate pool of future revenue, not revenue earned. The real core metric for second-tier CDMOs is conversion - orders into revenue, then into profit. Utilization and PAI-approved lines forecast the next quarter better than construction-in-progress does.

cxdmo.com industry desk

4. Risk: conversion is not one-way

A caveat: high conversion has a downside. When orders rush into commercial delivery, utilization and margin improve together - but so does the cost of a delivery miss. Asymchem called Q4 'a real challenge,' needing to book 28%-30% of full-year revenue in a single quarter; that is itself a stress test of capacity and supply chain, and whether it delivers on time will show up in 2027 renewals. Meanwhile, leaders are expanding aggressively, and strong current orders do not equal long-term shortage. If demand growth lags capacity release, falling utilization and new depreciation will compress margin at once - especially lethal for a second-tier CDMO spending one-tenth of the leaders' capex while betting on three new directions at once.

FAQ

FAQ

What is order conversion rate, and why does it matter more than backlog?

Backlog is a candidate pool of future revenue - it does not separate project stages, delivery timing or margin. Conversion measures how efficiently orders become revenue and then profit, tracked via 'schedule of new projects entering PPQ' and 'core-site utilization.' When two companies have similar backlogs, the one converting faster is the one that actually reaches the income statement.

Why haven't Jiuzhou's RMB 5bn peptide orders translated into revenue growth?

Because much of the order is still signed-but-unconverted: CDMO utilization is about 70%, the peptide commercial line is under construction, and the company admits growth is 'constrained by production scale.' New modalities typically need 18-36 months from signing to PPQ to commercial batches, so conversion requires capacity and certification to arrive together.

Was Apelo's Q3 margin decline a price war?

No. The company said order prices stayed relatively stable; the dip came from delivery mix - clinical projects outnumbered commercial ones in Q3, and small clinical batches with unfinished scale-up amortization carry lower margins (Q3 35.52% vs 40.39% for 9M). The real test is whether commercial delivery share recovers in Q4.

Is the gap between second-tier and leading CDMOs mostly about capacity?

More about certification and operating systems. Jiuzhou's ~RMB 1bn capex is roughly one-tenth of WuXi's, so it can only pick its battles; Asymchem calls the ability to win large clients a scarce 'ticket' - PAI checks, commercial batch releases and change-control histories cannot be bought with capex or a low price. So what is scarce is 'certified litres,' not litres alone.

This article is compiled from public reporting. Original source: Compiled from Q3 2026 reports and institutional calls of Jiuzhou Pharmaceutical, Apelo Pharmaceutical and Asymchem; 10jqka, Eastmoney, and related cxdmo.com coverage · For industry reference only; not investment advice.